You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for NOURIANZ


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NOURIANZ

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
NOURIANZ 40MG TAB Kyowa Kirin, Inc. 42747-0604-90 90 3650.38 40.55978 EACH 2023-01-01 - 2027-09-29 FSS
NOURIANZ 40MG TAB Kyowa Kirin, Inc. 42747-0604-90 90 3822.25 42.46944 EACH 2024-01-01 - 2027-09-29 Big4
NOURIANZ 20MG TAB Kyowa Kirin, Inc. 42747-0602-90 90 3401.81 37.79789 EACH 2022-09-30 - 2027-09-29 FSS
NOURIANZ 40MG TAB Kyowa Kirin, Inc. 42747-0604-90 90 5326.23 59.18033 EACH 2024-01-01 - 2027-09-29 FSS
NOURIANZ 20MG TAB Kyowa Kirin, Inc. 42747-0602-90 90 3617.27 40.19189 EACH 2023-01-01 - 2027-09-29 FSS
NOURIANZ 20MG TAB Kyowa Kirin, Inc. 42747-0602-90 90 3810.78 42.34200 EACH 2024-01-01 - 2027-09-29 Big4
NOURIANZ 20MG TAB Kyowa Kirin, Inc. 42747-0602-90 90 5326.23 59.18033 EACH 2024-01-01 - 2027-09-29 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NOURIANZ

Overview of NOURIANZ

NOURIANZ, containing the active ingredient istradefylline, is a xanthine derivative used as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease who experience "off" episodes. This drug is formulated as film-coated tablets for oral administration and is indicated to improve the wearing-off phenomena associated with levodopa-containing products[1][3][5].

Mechanism of Action and Dosage

NOURIANZ acts as an adenosine receptor antagonist, which helps in reducing the "off" time in patients with Parkinson's disease. The recommended dosage is 20 mg orally once daily, with the option to increase to a maximum of 40 mg once daily. It can be taken with or without food. For patients with moderate hepatic impairment, the maximum recommended dosage is 20 mg once daily, and it should be avoided in patients with severe hepatic impairment. Smokers may require a higher dosage of 40 mg once daily[1][3].

Market Dynamics

Addressable Patient Population

In the United States, there are approximately 1 million patients with Parkinson's disease, with about 433,000 of these patients experiencing "off" episodes, making them the target population for NOURIANZ. The market is growing slowly, with about 60,000 new patients each year. Half of the patients who initiate levodopa treatment will experience "off" episodes within five years[2].

Competitive Landscape

The Parkinson's disease market in the US is highly genericized, with 91.1% of prescriptions being generic. However, there remains a significant unmet need, particularly for novel mechanisms of action. NOURIANZ, with its unique mechanism as an adenosine receptor antagonist, positions itself well in this market despite the dominance of generic products[2].

Launch and Marketing Strategy

The launch of NOURIANZ in the US focused on raising awareness and understanding of its novel mechanism of action. The pricing strategy is competitive, with NOURIANZ priced in line with recently approved branded products, despite being an innovator in the market. The company is confident in the product's success, leveraging the FDA approval as a key factor in physician and patient acceptance[2].

Market Forecast and Insights

Market Size and Forecast

The market for NOURIANZ is expected to grow significantly over the next decade. The report from ResearchAndMarkets.com provides a detailed market assessment and forecast for NOURIANZ in the US and Japan from 2019 to 2032. The forecast indicates that the market scenario for Parkinson's disease will change due to extensive research and increased healthcare spending, allowing drug manufacturers to penetrate the market more effectively[1][3].

Sales Projections

The forecasted sales data for NOURIANZ from 2024 to 2032 show promising growth. The report includes detailed sales projections for both the US and Japan, which will help clients in making informed decisions about their therapeutic portfolios. The sales are expected to be influenced by the launch of late-stage emerging therapies and the competitive landscape of the Parkinson's disease market[1][3].

Price Projections and Cost Considerations

Pricing Strategy

NOURIANZ is priced competitively at around $50 per day, which is in line with other recently approved branded products in the Parkinson's disease market. Despite being in a highly genericized market, the pricing strategy aims to balance the innovative value of the drug with market acceptability[2].

Cost and Reimbursement

The cost of NOURIANZ, while significant, is manageable within the context of the overall treatment costs for Parkinson's disease. The drug's value proposition lies in its ability to reduce "off" time, which can significantly improve the quality of life for patients. Reimbursement strategies and patient access programs are likely to be crucial in ensuring that patients can afford this treatment[4].

Regulatory Milestones and Development Activities

Regulatory Status

NOURIANZ has received FDA approval, which is a critical milestone in its development. The report provides detailed insights into the regulatory milestones and other developmental activities, including clinical trials and patent information with expiry timelines[1][3].

Clinical Trials and Research

The drug has undergone extensive clinical trials, and the report covers the trial interventions, conditions, status, and completion dates. Ongoing research and development activities, including those in the US and Japan, are highlighted, providing a comprehensive overview of the drug's development scenario[1][3].

Competitive and Emerging Therapies

Competitive Landscape

The Parkinson's disease market is expected to see significant competition from other emerging therapies. The report includes a comprehensive overview of market competitors and late-stage emerging therapies that could impact NOURIANZ's market position. These therapies are focusing on novel approaches to treat and improve the disease condition, which may challenge NOURIANZ's dominance[1][3].

Emerging Therapies

Other products under development, such as KW-6356, are expected to provide tough competition. These therapies aim to delay symptom onset and potentially offer disease-modifying effects, which could alter the market dynamics in the future[2].

SWOT Analysis and Analyst Views

Strengths, Weaknesses, Opportunities, and Threats

The report features a SWOT analysis that highlights the strengths of NOURIANZ, such as its novel mechanism of action and FDA approval. It also identifies weaknesses, opportunities, and threats, including the highly genericized market and the emergence of new therapies. Analyst views provide additional insights into the market position and future prospects of NOURIANZ[1][3].

Key Takeaways

  • Novel Mechanism of Action: NOURIANZ acts as an adenosine receptor antagonist, offering a unique approach to reducing "off" time in Parkinson's disease patients.
  • Market Growth: The market for NOURIANZ is expected to grow significantly due to increased healthcare spending and the need for innovative treatments.
  • Competitive Pricing: NOURIANZ is priced competitively with other branded products in the market.
  • Regulatory Milestones: FDA approval is a key factor in the drug's success and acceptance.
  • Emerging Competition: Late-stage emerging therapies could significantly impact the market dynamics and NOURIANZ's market position.

FAQs

What is the primary indication for NOURIANZ?

NOURIANZ is indicated as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes[1][3].

How is NOURIANZ administered?

NOURIANZ is administered orally once daily, with a recommended dosage of 20 mg that can be increased to a maximum of 40 mg once daily[1][3].

What is the competitive landscape like for NOURIANZ in the US?

The US market for Parkinson's disease is highly genericized, but NOURIANZ's novel mechanism of action positions it well to address unmet needs in this market[2].

What are the forecasted sales projections for NOURIANZ?

The forecasted sales data for NOURIANZ from 2024 to 2032 indicate significant growth, driven by increased healthcare spending and the need for innovative treatments[1][3].

How does NOURIANZ compare to other emerging therapies for Parkinson's disease?

NOURIANZ faces competition from late-stage emerging therapies that are focusing on novel approaches to treat and improve Parkinson's disease. These therapies may offer additional benefits such as disease-modifying effects[2].

Sources

  1. ResearchAndMarkets.com: "NOURIANZ Market Size, Forecast, and Market Insight - 2032"[1]
  2. Kyowa Kirin: "Transcript of Updates on Nourianz Marketing Strategy in the US and Japan"[2]
  3. BusinessWire: "NOURIANZ in Parkinson's Disease Treatment Landscape by 2032"[3]
  4. DrugPatentWatch: "Latest pharmaceutical drug prices and trends for NDC 42747-0726"[4]
  5. GlobalData: "Net Present Value Model: Nourianz"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.